The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells

  • Authors:
    • Gege Chen
    • Zhijian Xu
    • Gaomei Chang
    • Jun Hou
    • Liangning Hu
    • Yiwen Zhang
    • Dandan Yu
    • Bo Li
    • Shuaikang Chang
    • Yongsheng Xie
    • Yong Zhang
    • Rong Wei
    • Huiqun Wu
    • Wenqin Xiao
    • Xi Sun
    • Yi Tao
    • Lu Gao
    • Bojie Dai
    • Jumei Shi
    • Weiliang Zhu
  • View Affiliations

  • Published online on: May 30, 2017     https://doi.org/10.3892/or.2017.5675
  • Pages: 488-496
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Multiple myeloma (MM) is an incurable hematologic malignancy because of its drug resistance. Pterostilbene (Pter) is found mainly in blueberries and grapes. The effects of Pter and its exact pharmacologic mechanisms on chemoresistant myeloma are not known. Herein, we investigated the anti-myeloma activity of Pter in bortezomib-resistant cell line H929R and explored the related mechanism of action for the first time. We found that Pter inhibited proliferation of H929R cells and promoted apoptosis of the cells through a caspase-dependent pathway, loss of mitochondrial membrane potential, and activation of Akt and p38 mitogen-activated protein kinase (MAPK) signaling pathways. DNA damage and S-phase arrest might be involved in Pter-related toxicity in H929R cells. Pter and the histone deacetylase inhibitors panobinostat or vorinostat inhibited proliferation of H929R cells in a synergistic manner. These data supported that Pter might be a promising natural compound for relapsed/refractory myeloma therapy, especially against myeloma resistant to bortezomib chemotherapy.
View Figures
View References

Related Articles

Journal Cover

July-2017
Volume 38 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen G, Xu Z, Chang G, Hou J, Hu L, Zhang Y, Yu D, Li B, Chang S, Xie Y, Xie Y, et al: The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells. Oncol Rep 38: 488-496, 2017.
APA
Chen, G., Xu, Z., Chang, G., Hou, J., Hu, L., Zhang, Y. ... Zhu, W. (2017). The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells. Oncology Reports, 38, 488-496. https://doi.org/10.3892/or.2017.5675
MLA
Chen, G., Xu, Z., Chang, G., Hou, J., Hu, L., Zhang, Y., Yu, D., Li, B., Chang, S., Xie, Y., Zhang, Y., Wei, R., Wu, H., Xiao, W., Sun, X., Tao, Y., Gao, L., Dai, B., Shi, J., Zhu, W."The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells". Oncology Reports 38.1 (2017): 488-496.
Chicago
Chen, G., Xu, Z., Chang, G., Hou, J., Hu, L., Zhang, Y., Yu, D., Li, B., Chang, S., Xie, Y., Zhang, Y., Wei, R., Wu, H., Xiao, W., Sun, X., Tao, Y., Gao, L., Dai, B., Shi, J., Zhu, W."The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells". Oncology Reports 38, no. 1 (2017): 488-496. https://doi.org/10.3892/or.2017.5675